Posted by law663 on December 6, 2005, at 1:40:12
Somerset Announces Revised FDA PDUFA Date for EMSAM(R) (Selegiline Transdermal System)
Monday November 21, 4:15 pm ETTAMPA, Fla., Nov. 21 /PRNewswire/ -- Somerset Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Division of Psychopharmacologic Drugs has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2006 for EMSAM® (selegiline transdermal system), an investigational transdermal patch for the acute and maintenance treatment of major depressive disorder. The PDUFA goal date was extended by three months in order to allow the FDA sufficient time to review an amendment to Somerset's NDA submitted following the recommendations of the U.S. Food and Drug Administration's Psychopharmacologic Drug Advisory Committee.
ADVERTISEMENT
On October 26, 2005 the Psychopharmacologic Drug Advisory Committee voted EMSAM® (selegiline transdermal system) could be safely administered without tyramine dietary modifications at 20 mg. EMSAM 30 and 40 mg will be administered with tyramine dietary modifications as originally proposed by Somerset. The Committee also agreed that Somerset and Bristol-Myers Squibb could effectively communicate dietary instructions required at the higher doses, without requiring the same dietary instructions for the 20 mg dose. However, the FDA is not bound by the Committee's recommendations.EMSAM received an "approvable" letter from the FDA on January 30, 2004 and would be the first transdermal patch for the treatment of major depressive disorder upon final approval. EMSAM is an irreversible monoamine oxidase inhibitor that, when applied to the skin, is designed to deliver selegiline continuously over a 24-hour period. In December 2004, Somerset and Bristol- Myers Squibb entered into an agreement for the commercialization and distribution of EMSAM.
Somerset Pharmaceuticals, Inc. is a joint venture between Mylan Laboratories (NYSE: MYL - News) and Watson Pharmaceuticals, Inc. (NYSE: WPI - News). For more information about Somerset, visit www.somersetpharm.com.
Forward-Looking Statement
The parties caution that this press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual future results may differ materially from those expressed or implied by such forward-looking statements due to such factors including, but not limited to, changing market conditions, the availability and cost of raw materials, the impact of competitive products and pricing, the timely development, FDA approval, and market acceptance of Somerset's and its competitors' products, the outcome of litigation and other risks detailed from time to time in the Securities and Exchange Commission filings of Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc. Except as required by law, the parties undertake no obligation to update these statements for revisions or changes after the date of this release.
poster:law663
thread:585987
URL: http://www.dr-bob.org/babble/20051203/msgs/585987.html